Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer (Q39278116)

10 September 2017

1 reference

title

Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer (English)

1 reference

10 September 2017

main subject

phase I clinical trial

0 references

phase II clinical trial

0 references

Rafael Rosell

1 reference

10 September 2017

Niki Karachaliou

1 reference

10 September 2017

Mariacarmela Santarpia

1 reference

10 September 2017

Maria Gonzalez Cao

1 reference

10 September 2017

Cristina Teixido

1 reference

10 September 2017

Aaron E Sosa

1 reference

10 September 2017

Jordi Berenguer

1 reference

10 September 2017

Alejandra Rodriguez Capote

1 reference

10 September 2017

Giuseppe Altavilla

1 reference

10 September 2017

language of work or name

English

0 references

publication date

2 May 2017

1 reference

Expert Opinion on Investigational Drugs

10 September 2017

published in

1 reference

10 September 2017

1 reference

10 September 2017

1 reference

10 September 2017

page(s)

713-722

1 reference

10 September 2017

cites work

Cancer statistics, 2016

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

The biology and treatment of EML4-ALK non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Microtubule association of EML proteins and the EML4-ALK variant 3 oncoprotein require an N-terminal trimerization domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Human EML4, a novel member of the EMAP family, is essential for microtubule formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Optimal detection of ALK rearranged lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Ceritinib in ALK-rearranged non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Circumventing cancer drug resistance in the era of personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Patient-derived models of acquired resistance can identify effective drug combinations for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Targeting ALK: Precision Medicine Takes on Drug Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC: Topic: Medical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1324572

10.1080/13543784.2017.1324572

21 January 2018

Identifiers

DOI

1 reference

10 September 2017

1 reference